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KESAN INULIN KE ATAS BIOKEPEROLEHAN ORAL MINERAL DAN DRUG 
 
 
 ABSTRAK 
  
 
Kajian ini dijalankan untuk menyiasat potensi inulin dan kesan dos-dos inulin yang  
 
berbeza dalam peningkatan penyerapan oral zink dan magnesium. Kesan dos-dos inulin  
 
yang berbeza dalam biokeperolehan kedua-dua model drug oral, acyclovir dan atenolol,  
 
juga telah disiasat. Sebelum kajian tersebut, dua kaedah spektrometer nyala serapan  
 
atom yang ringkas, pantas dan sensitive telah berjaya dibangunkan untuk menentukan  
 
kepekatan zink dan magnesium dalam plasma tikus. Ketepatan nilainya adalah di antara  
 
91-107% untuk zink dan 92-105% untuk magnesium. Manakala semua kejituan nilainya  
 
adalah kurang daripada 12.5% untuk kedua-dua zink dan magnesium. Penyerapan zink  
 
dan magnesium adalah tidak lengkap selepas diberikan secara oral. Ini mungkin  
 
disebabkan oleh sistem homeostatis dalam badan untuk mengimbangkan kandungan  
 
mineral di dalam lingkungan yang sempit. Satu dos tunggal inulin sebanyak 45 mg  
 
diberikan bersama dengan zink dan magnesium dapat meningkatkan oral biokeperolehan  
 
kedua-dua mineral tersebut. Walaubagaimanapun, oral biokeperolehan untuk zink dan  
 
magnesium tidak ditingkatkan secara signifikan jikalau dos inulin bertambah daripada  
 
45 mg sehingga 135 mg. Keadaan ini mungkin disebabkan oleh mekanisme peningkatan  
 
dalam penyerapan zink dan magnesium adalah melalui pengaktifan calmodulin yang  
 
berkaitan dengan jalur paracellular. Dalam kajian selanjutnya, satu dos tunggal 45 mg  
 
inulin juga didapati dapat meningkatkan biokeperolehan acyclovir dan atenolol  
 
sebanyak 1.37 dan 1.24 kali, di mana drug adalah dikelaskan dalam BCS kelas III  
 
dengan ketelapan usus yang kurang berkesan. Adalah juga dipercayai inulin dapat  
 
membuka persimpangan ketat dan seterusnya meningkatkan ketelapan usus acyclovir  
 
dan atenolol. Peningkatan dalam dos inulin daripada 45 mg kepada 135 mg tidak dapat  
 
meningkatkan penyerapan kedua-dua drug model secara signifikan.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EFFECT OF INULIN ON ORAL BIOAVAILABILITY OF MINERALS AND DRUGS 
 
ABSTRACT 
  
 
The present study was conducted to evaluate the potential and effect of different doses  
 
of inulin in enhancing the oral absorption of zinc and magnesium. The effect of different  
 
doses of inulin in the oral bioavailability of the 2 model drugs, acyclovir and atenolol,  
 
was also assessed. Prior to the study, two simple, rapid and sensitive flame atomic  
 
absorption spectrophotometer methods were successfully developed for the  
 
determination of zinc and magnesium in rat plasma, respectively. The accuracy values  
 
were between 91 – 107% for zinc and 92 – 105% for magnesium, while the coefficient  
 
of variation values were all less than 12.5% for both zinc and magnesium. The  
 
absorption of zinc and magnesium was incomplete upon oral administration. This  
 
could be due to the existing homeostasis system in the body to regulate mineral content  
 
within a narrow range. A single dose of inulin with 45 mg co-administration was  
 
capable of increasing the extent of oral absorption of zinc and magnesium. However, the 
 
 oral absorption was not significantly increased with the increasing dose of inulin from  
 
45 mg until 135 mg. The possible underlying mechanism for the enhancement of zinc  
 
and magnesium absorption was via the activation of calmodulin associated paracellular  
 
pathway by inulin. In the subsequent study, a single dose of 45 mg inulin was also able  
 
to increase the bioavailability of acyclovir and atenolol by 1.37 and 1.24-fold, which  
 
belong to BCS class III drugs with poor intestinal permeability. It was postulated that  
 
the inulin could open up the tight junction and thus increase the intestinal permeability  
 
of acyclovir and atenolol. An increase in the dose of inulin from 45 mg to 135 mg did  
 
not increase the absorption of the 2 model drugs significantly.  
CHAPTER 1  
 
 INTRODUCTION 
 
 
1.2  DRUG DELIVERY 
 
INTRODUCTION 
 
In order to optimize the desired therapeutic response of a drug, the correct amount  
 
should be delivered to the site of action at the correct rate, timing and duration. Drugs  
 
can be delievered by enteral, transdermal, parenteral, inhalation, or intranasal  
 
administration. Each route may serve a different purpose and has its own advantages and  
 
disadvantages. For example, intravenous injection can be given to obtain immediate  
 
effect and maximal bioavailability, but the potential for adverse reaction to occur also  
 
increases. Inhalation may be used for local or systemic effects, however, it may  
 
stimulate cough reflex (Shargel et al., 2005). Among the different modes of drug  
 
administration, the oral route is still the most preferred due to its safety, efficiency and  
 
accessibility with minimal discomfort to the patient in comparison with the other routes  
 
(Pefri & Lennernäs, 2003). 
 
 
1.1.2  MEMBRANE TRANSPORT MECHANISM 
 
For drugs to be absorbed from the gastrointestinal tract after oral administration, they  
 
must be protected from enzyme degradation and traverse through the barrier membrane  
 
into the blood stream (Semalty et al., 2007). Transmembrane movement of drugs is  
 
influenced by the composition and structure of the cell membrane. 
 
 
The cell membrane is a thin layer of approximately 70 to 100 Å in thickness. It is  
 
composed of 2 layers of phospholipids, amphipathic molecules, proteins and  
carbohydrates. The phospholipid layers are arranged so that the hydrophilic “head”  
 
groups will face the extracellular water environment, while the hydrophobic “tail”  
 
groups are aligned to the interior. This explains the observation that hydrophobic drugs  
 
tend to penetrate barrier membrane more easily (Shargel et al., 2005). There are also  
 
pores present in cell membranes and they provide channels for the movement of water,  
 
urea and certain charged ions. Figure 1.1 shows the structure of a plasma membrane.  
 
The different proteins present on the surface of cell membranes also function as cell  
 
surface receptors and transporters for various drugs and molecules. Transport of drugs  
 
across the membrane barrier can occur transcellularly or paracellularly.   
 
 
 
 
                       
                         Figure 1.1  Structure of a cell membrane 
 
 
 
1.1.2.1 TRANSCELLULAR 
 
Transcellular transport is thought to be the main route of absorption of many drugs and  
 
is related to the hydrophobicity of the molecule (Pefri & Lennernäs, 2003). It  
 
involves transfer of drugs and macromolecules across the epithelial cellular membrane  
 
(Hsieh, 1993). Various mechanisms are involved in this transcellular transport of drugs. 
  
1.1.2.1(a)  SIMPLE PASSIVE DIFFUSION 
 
Passive diffusion is the process by which molecules spontaneously diffuse from a region  
 
of higher concentration to a region of lower concentration without the assistance of a  
 
transport protein and expenditure of energy (Shargel et al., 2005). It is the preferred  
 
route of transport for small molecules and lipophilic molecules. The rate of penetration  
 
of a drug across the membrane follows Fick’s law as shown below: 
 
                                                            
                                      rate of penetration= (DK/δ)A · ∆C               (1.1) 
 
 
in which A = surface area 
 
            ∆C = concentration difference across the membrane  
 
              D = diffusivity of the solute  
 
              K = partition coefficient between membrane and water 
 
               δ = membrane thickness 
 
The partition coefficient, K, is an important determinant of the rate of transfer across  
 
membranes. Many lipid-soluble molecules such as oxygen, nitrogen gas, carbon dioxide  
 
and benzopyrene are transported by simple diffusion (Oh & Amidon, 1999).   
 
 
1.1.2.1(b)  CARRIER-MEDIATED TRANSPORT 
 
Carrier-mediated transport is the transport system in which substances can be  
 
transferred through the lipid phase of biological membrane using a carrier or specialized  
 
system (Pefri & Lennernäs, 2003). Many of the compounds transported via this  
 
mechanism are polar, with low lipid solubility. This transport system is characterized by  
 
(1) being saturable and (2) subjected to inhibition by competitive inhibitors. There are 
two types of carrier-mediated transport: active transport and facilitated diffusion.  
 
Active transport results in an accumulation of a solute on one side of membrane and  
 
often against the electrochemical gradient. During this process, energy is required to  
 
move ions or molecules against the electrochemical potential gradients (Oh &  
 
Amidon, 1999). The transportation involves binding of the drug to a carrier to form a  
 
carrier-drug complex that shuttles the drug across the membrane. The drug is then 
 
 dissociated from the carrier once it has crossed the membrane. Examples of active  
 
transport include intestinal absorption of some amino-β-lactam antibiotics and  
 
angiotensin-converting enzyme inhibitors via the dipeptide transport system (Rowland  
 
& Tozer, 1995). 
 
 
In contrast to active transport, energy source is not needed for facilitated diffusion.  
 
Molecules enter and leave cell by following their electrochemical potential gradient  
 
(Oh & Amidon, 1999). However, similar to active transport, it involves a carrier, is  
 
saturable, selective for the drug and shows competition kinetics for drugs of similar  
 
structures. The binding site alternates between 2 states: exposure to one side first, and  
 
then to the other side of the membrane (Oh & Amidon, 1999). Only a few drugs  
 
undergo passive facilitated diffusion. An example is the transport of vitamin B12 across  
 
the gastrointestinal epithelium (Rowland & Tozer, 1995).       
 
 
1.1.2.1(c)  ENDOCYTOSIS 
 
Most of the transportation of macromolecules is mediated by endocytosis. During the  
 
process, ? inimize? cules are engulfed by the cell membrane, migrate to the perinuclear  
 
region within membrane-bound vehicles, where the vehicles coalesce with lysosomes  
 
and release the macromolecules (Hsieh, 1993). Endocytosis process includes  
 
pinocytosis, receptor-mediated endocytosis, phagocytosis and transcytosis (Boer, 1994). 
 
 
1.1.2.2 PARACELULAR 
 
In paracellular transport, the drug is transferred through the intercellular spaces of the  
 
cell membrane. This pathway is governed by tight junctions. The complexity of the tight  
 
junction fibril branching pattern is thought to influence the permeability of tight  
 
junctions (Boer, 1994). Pauletti et al. (1997) reported that the transportation of drug  
 
through the tight junctions is dependent on the size and charge of the drug. Generally,  
 
small hydrophilic solutes traverse the membrane barrier predominantly via this  
 
paracellular route (Pauletti et al., 1997). A study conducted by Saitoh et al. (2004)  
 
demonstrated that hydrophilic drugs like ketoprofen, imipramine, zidovudine are  
 
transported using the paracellular route. As reviewed by Itallie & Anderson (2004),  
 
paracellular transport differs from transcellular transport in two ways. First, it is  
 
exclusively passive, driven by electroosmotic gradients. Second, it shows identical  
 
selectivity and conductance in both the mucosal and serosal sides. There is a growing  
 
interest in employing the paracellular pathway to promote the transport of metabolically  
 
labile peptide drugs, with the expectation that the paracellular space is deficient in  
 
proteolytic enzymes (Boer, 1994).       
 
 
1.1.3  DELIVERY VEHICLES 
 
Although there exists different transport mechanisms to facilitate drug transportation,  
 
limited absorption still exists for certain drugs due to the presence of physiological,  
 
biochemical and chemical barriers. Hence, researchers have come out with various ways  
 
and means to increase the absorption of these drugs. These include co-administration of  
 
enzyme inhibitiors, use of suitable carriers, bioadhesion and permeation enhancers as  
 
well as converting them into prodrugs. 
 
 
1.1.3(a)  CO-ADMINISTRATION OF ENZYME INHIBITORS 
 
Degradation by enzyme in the gastrointestinal tract is one of the main obstacles in  
 
achieving good bioavailability for some drugs, especially biopharmaceuticals. To  
 
circumvent the degradation, co-administration of enzyme inhibitors have been explored  
 
(Semalty et al., 2007). Esterases, secreted by the pancrease, play a crucial role in the  
 
presystemic metabolism of many drugs which bear ester moieties. Consequently,  
 
specific inhibition of the responsible esterase may be useful in enhancing the oral  
 
bioavailability of a susceptible drug. Li et al. (2007) demonstrated that co-administration  
 
of grapefruit juice could inhibit the esterase activity and increase the absorption of  
 
lovastatin and enalapril in rats. Although enzyme inhibitors can enhance drug absorption,  
 
there are concerns on the toxicity of the enzyme inhibitors. Moreover, the dilution effect  
 
during gastrointestinal passage necessitates the administration of high concentration of  
 
inhibitors in order to exert the inhibitory effect. 
 
 
1.1.3(b)  CARRIERS 
 
In order to prevent degradation from GI enzymes as well as to improve the absorption of  
 
drugs, carriers like liposomes, nanoparticles, glycoproteins, synthetic polymers and  
 
lipoproteins have been employed to improve the oral delivery into the systemic  
 
circulation. Drugs can either be covalently attached to the carrier molecules or entrapped  
 
within the carrier matrix (Banker & Rhodes, 2002). One of the advantages of using  
 
carriers likes liposomes or nanoparticles is that drug absorption can be enhanced through  
 
transport via the Peyer’s patches or other lipid absorption mechanisms (Lieberman et  
 
al., 1996). Absorption by Peyer’s patches can help to circumvent presystemic  
 
metabolism in the liver. In certain cases, physicochemical properties of the carriers such  
 
as size, shape, specific surface area and surface charge can affect the absorption of the  
 
drugs. Sakuma et al. (2002) showed that the enhancement in absorption of salmon  
 
calcitonin could be achieved through the optimization of the chemical structure of  
 
nanoparticles by introducing cationic poly-vinylamine (PVAm) groups to the surface of  
 
the poly-N-isopropylacrylamide (PNIPAAm) nanoparticles. 
 
 
1.1.3(c)  PRODRUG  
 
A prodrug is a pharmacologically inert form of an active drug that must undergo  
 
transformation to the active parent compound in vivo by either a chemical or an  
 
enzymatic reaction to exert its therapeutic effects (Banker & Rhodes, 2002). Some  
 
authors designed prodrugs by chemical attachment to the parent molecules of a variety  
 
of pro-moieties to functional groups such as carboxyl, hydroxyl, amine, imine,  
 
phosphate and CH-acidic (Pefri & Lennernäs, 2003). Prodrugs can be used to  
 
increase oral bioavailability of drug by improving solubility and membrane permeability  
 
as well as  by reducing the influence of by efflux transporters in the gastrointestinal tract  
 
(Stella, 2007). Chae et al. (2007) has demonstrated that VP-0502AL, a prodrug of  
 
an anti-human immunodeficiency virus drug, VP-0502, had better oral bioavailability  
 
than the parent compound VP-0502 itself in rats. The improvement in absorption might  
 
be due to the enhancement of drug solubility by attaching an amino acid, alanine to the  
 
drug.         
1.1.3(d)  BIOADHESION 
 
Bioadhesives are materials that bind to biological substrates such as membrane surface  
 
or mucin layers. They are capable of being retained on biological membranes for an  
 
extended period of time and serve to increase the dosage form residence time in the  
 
gastrointestinal tract. Moreover, they can be used to improve intimacy of contact with  
 
various absorptive membranes of the biological system (Gupta et al., 1990).  
 
Prolonged contact time of a drug with a body tissue, through the use of a bioadhesive  
 
polymer, can significantly improve the absorption of many drugs. This has been shown  
 
by Tur et al. (1997) that a bioadhesive polymer, poly (acrylic acid) crosslinked with 2,5- 
 
dimethyl-1,5-hexadiene, was able to improve the absorption of griseofulvin. They  
 
suggested that the increment in absorption might be due to an increase in the  
 
gastrointestinal transit time and the close contact of griseofulvin with the absorbing  
 
membrane brought about by the bioadhesive polymer. 
 
 
1.1.3(e)  PERMEATION ENHANCER 
 
In recent years, permeation enhancers have been increasingly used to improve the oral  
 
absorption of large hydrophilic drugs. Permeation enhancers can disrupt the integrity of  
 
the membrane barrier in the gastrointestinal tract in a number of ways: increasing the  
 
fluidity of cell membrane, extracting inter- and intracellular lipids, disrupting lipid  
 
structure, altering cellular proteins, increasing the thermodynamic activity of a drug,  
 
overcoming enzymatic barriers and altering surface mucin rheology (Touitou & Barry,  
 
2006). As reviewed by Ward et al. (2000), a variety of exogenous compounds have been  
 
identified to have the ability to increase the paracellular permeability. They include  
 
calcium chelators, surfactants, medium chain fatty acids and cationic polymers. The 
 effectiveness of permeation enhancers can be influenced by many factors including the  
 
physiochemical properties of the drugs, administration site of the permeation enhancers  
 
and species di fferences (Knäblein ,  2005).  An ideal  enhancer should be  
 
pharmacologically inert, not toxic and provides immediate onset of action. Moreover,  
 
normal barrier properties of the gastrointestinal tract should recover immediately when  
 
the enhancer is removed (Hsieh, 1993).   
 
 
1.2 INULIN 
 
1.2.1 INTRODUCTION 
 
Inulin is a type of plant storage carbohydrate that can be found in several fruits and  
 
vegetables including banana, onion, leek, chicory, garlic and wheat.  It can also be found  
 
in some bacteria and fungi. The role of inulin in plants is mostly documented as a long- 
 
term reserve carbohydrate stored in underground overwintering organs of plants. It is  
 
also referred as a cryoprotectant and osmotic regulator which allows the plants to  
 
survive and grow under conditions of water shortage (Stephen et al., 2006). 
 
 
Inulin is a polydisperse fructan (Phelps, 1965) which consists mainly of ß(2→1)  
 
fructosyl-fructose linkages. A glucose moiety can link to the starting point of inulin by  
 
α(1→2) bond (Niness, 1999). The chemical structure of inulin is shown in Figure 1.2.  
 
Functionality of inulin can be influenced by the degree of polymerization (DP) and  
 
presence of branches. DP and presence of branches can vary according to plant species,  
 
weather conditions and physiological ages of the plant (Franck & Leenheer 2005).   
 
 
 
 
                                    
 
                               
                                   Figure 1.2  Chemical structure of inulin 
 
 
Today, chicory is the only plant that has been used industrially for the extraction of  
 
inulin. Two phases are required for the production of inulin. The first phase involves  
 
extraction with hot water in a countercurrent diffuser and a primary purification step is  
 
applied to the extraction juice by liming and carbonation at high pH, yielding an impure  
 
syrup. The second phase is a refining phase using cationic and anionic ion exchange  
 
resins for demineralization and active carbon for decolorization. Pure inulin can be  
 
obtained after the juice is passed over a 0.2 µm filter to be sterilized, evaporated and  
 
spray-dried (Stephen et al., 2006). The production process is shown in Figure 1.3. 
 
 
 
 
 
 
 
 
 
 
                                                   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Figure 1.3 Production process of inulin (Stephen et al., 2006) 
 
 
Chicory inulin can be derivatized into different forms through different chemical and  
 
physical processes. Chicory inulin varies from 2 to 60 units (DPav=12), can  
 
undergo partial enzymatic hydrolysis using endo-inulinase to produce oligofructose, in  
 
which the DP varies from 2 to 7 (DPav=4). Long-chain inulin or inulin HP  
 
with DP of 10 to 60 (DPav=25), is produced by applying physical separation  
 
techniques to eliminate all oligomers with a DP<10. Mixtures of oligofructose and  
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inulin HP are available commercially, such as Synergy® 1(Roberfroid, 2005, Roberfroid,  
 
2004). The term inulin-type fructans covers all ß(2→1) linear fructans including native  
 
inulin, oligofructose, inulin HP and Synergy® 1(Roberfroid, 2007). 
 
 
1.2.2 POTENTIAL THERAPEUTIC BENEFITS OF INULIN 
  
1.2.2(a)  PREBIOTIC 
 
Gibson and Roberfroid (2008) defined prebiotic as a nondigestible food ingredient that  
 
beneficially affects the host by selectively stimulating the growth or activity of one or a  
 
limited number of bacteria in the colon, and thus improves host health.  
 
 
Inulin resists hydrolysis and absorption in the upper intestine as the pancreas, gastric and  
 
small intestine are not able to produce enzyme which can split ß(2→1) fructosyl- 
 
fructose linkages of inulin (Cherbut, 2002). This has been further proven by Ellegård et  
 
al. (1997) who performed a double blind crossover study with inulin and oligofructose  
 
in 10 patients with conventional ileostomy. The percentages of Inulin and oligofructose  
 
recovered in the ileostomy effluent were 88% and 89%, respectively. As inulin which  
 
escaped digestion in the upper gastrointestinal tract was not recovered in the stools,  
 
indicated that the portion reaching the colon was completely fermented by colonic flora  
 
(Molis et al., 1996).  
 
 
In a study reported by Propst et al., (2003), the end product of microflora fermentation,  
 
namely short chain fatty acid (SCFA), was increased in the faeces of healthy adult dogs  
 
after being fed inulin and oligofructose as compared with control. Inulin and  
 
oligosaccharides have been shown to increase Bifidobacterium and Lactobacillus  
 
population that are perceived to have health-promoting properties (Gibson and  
Roberfroid, 2008; Blay et al., 1999).  Rada et al. (2001) also demonstrated in a study  
 
that caecal bifidobacterial concentration was increased for more than 3-fold in inulin- 
 
treated laying hens. Moreover, Bifidobacterium and Lactobacillus can help to maintain  
 
the health of host by suppressing pathogenic bacteria such as E. coli and Salmonella  
 
typhimurium.  
 
 
1.2.2(b)  PREVENTION OF COLORECTAL CANCER (CRC) 
 
Family history, dietary pattern, lifestyle exposure patterns and physical activities are   
 
factors which can increase CRC risks (Potter, 1999). Healthy diet intake is one of the  
 
ways for CRC prevention. 
 
 
Genetic mutations in the gut can lead to aberrant crypt foci (ACF) and grow into polyps  
 
or adenomas, which are recognized as early key determinants of CRC. Verghese et al.,  
 
(2002) has shown that long-chain inulin was able to suppress azoxymethane-induced  
 
ACF formation in rats in a dose dependent manner. The suppression effect was even  
 
more significant when the rats were treated with both inulin and probiotics together  
 
(Femia et al., 2002).   
 
 
Apoptosis is also an important regulatory process in the protection against the  
 
development of cancer. In a study conducted by Leu et al., (2005), inulin together with  
 
probiotic, Bifidobacterium lactis, could elevate acute apoptotic response to a genotoxic  
 
carcinogen in distal colon of rats. It was speculated that inulin could decrease the  
 
colonic pH, produce SCFA or change the balance of microfloral species which enabled  
 
B.lactis to exert proapototic effect. 
 
 
1.2.2(c)  PREVENTION OF ATHEROSCLEROSIS 
 
Many studies have demonstrated the importance of plasma triglyceride levels as a risk  
 
factor for atherosclerosis (Hokanson & Austin, 1996; Austin et al., 1998). Klag et al.  
 
(1993) also reported that there was a strong correlation between plasma cholesterol and  
 
atherosclerosis.  
 
 
In a study conducted in male golden Syrian hamsters, which were randomly assigned to  
 
four diet groups containing 0 (control), 8, 12, and 16% inulin respectively, it was  
 
observed that dietary inulin managed to decrease very low-density lipoprotein (VLDL)  
 
cholesterol, plasma triacylglycerol and hepatic total cholesterol. Daily fecal bile acid  
 
excretion also increased when compared with controls (Trautwein et al., 1998).  
 
Letexier et al., (2003) showed that inulin was able to reduce plasma triacylglycerol  
 
concentrations and hepatic lipogenesis in humans. The effect of inulin in attenuating  
 
atherosclerosis was also supported by the study of Rault-Nania et al., (2006) which  
 
showed that plasma cholesterol concentration, plasma triacylglycerol concentration,  
 
hepatic cholesterol concentration as well as hepatic triacylgycerol concentration were  
 
reduced in apolipoprotein E-deficient mice which fed with inulin. Mice fed with inulin  
 
also had less atherosclerotic lesion area compared with control. 
 
 
There are a few speculations for the underlying mechanisms. They include altered  
 
hepatic triacylglycerol synthesis and VLDL secretion, impaired reabsorption of  
 
circulating bile acids and changes in lipid metabolism (Trautwein et al., 1998; Beylot,  
 
2005; Rault-Nania et al., 2006).   
 
 
 
1.2.2(d)  ENHANCEMENT OF CALCIUM ABSORPTION 
 
Calcium and phosphorus ions are required for normal bone formation. Calcium  
 
deficiency can impair mineralization and increase bone resorption. This can result in  
 
bone fractures and osteoporosis. Hence, calcium intake is one of the ways for the  
 
prevention of osteoporosis.  
 
 
Inulin-type fructans have been shown to increase calcium transport in vitro via the 
 
paracellular route (Mineo et al., 2001; Suzuki and Hara, 2004). In rat studies,  
 
bone mineral density, bone mineral content and calcium absorption were significant  
 
increased in inulin-fed groups (Kruger et al., 2003; Zafar et al., 2004, Coudray et al.,  
 
2005). Several hypotheses have been put forward to explain the mechanisms involved.  
 
They include the production of SCFA that would acidify the luminal contents,  
 
enhancing minerals solubility and hence absorption, or enhancement of another  
 
mechanism via calbindinD9k (Kruger et al., 2003). Positive results in calcium  
 
absorption were also observed in adolescents (Heuvel et al., 1999, Griffin, 2003).  
 
 
According to Parhami et al. (2000), atherosclerosis and bone loss are interwoven. Lipid- 
 
lowering agents are able to reduce atherosclerosis, vascular calcification as well as  
 
osteoporotic fractures. Hence inulin, which is able to help in attenuating atherosclerosis  
 
as mentioned earlier, may protect the bone indirectly.  
 
 
1.2.2(e)  IMPROVEMENT OF IMMUNE SYSTEM 
 
Cebra (1999) reported the important roles of microflora on intestinal immune system  
 
development. Bifidobacteria and lactobacilli are two probiotics which can activate host  
 
immune system and affect goblet cell dynamics (Deplancke & Gaskins, 2001), suppress  
pathogenic bacteria (Kolida et al., 2002) and treat intestinal inflammation (Bai &  
 
Quyang, 2006). Consequently inulin, which is able to stimulate the growth of  
 
bifidobacteria and lactobacillus (Buddington et al., 1996; Kleessen et al., 1997;  
 
Niness, 1999; Blay et al., 1999; Watzl et al., 2005) is able to enhance the immune  
 
system indirectly.   
 
 
Other than the benefits mentioned above, inulin showed a better laxative effect in  
 
elderly. Thus helping to prevent constipation (Kleessen et al., 1997). It could also  
 
decrease ß-glucuronidase and glycocholic acid hydroxylase activities which were  
 
associated with the conversion of procarcinogens to carcinogens in humans (Buddington  
 
et al., 1996). It has been shown to reduce the incidences of ACF in the distal colon,  
 
lower the densities of C. albicans, and increased the resistance to L. monocytogenes and  
 
S. typhimurium in inulin-fed mice (Buddington et al., 2002). In a recent study,  
 
Benyacoub et al., (2008) reported that inulin was able to stimulate mucosal immunity  
 
and improve the efficacy of a vaccine upon challenge with virulent Salmonella by  
 
increasing the activity of immunoglobin G, fecal immunoglobin A as well as the  
 
phagocytic activity of the peritoneal macrophage. 
 
 
1.3  ZINC 
 
1.3.1 INTRODUCTION 
 
Zinc is an essential trace element in human nutrition. Adult contains approximately 2 to  
 
3 grams of zinc throughout the body with the highest concentration in the muscle and 
  
bone. Zinc plays catalytic, structural or regulatory roles in more than 200  
 
metalloenzymes and metalloproteins which are involved in protein and nucleic acid  
 
metabolism and energy production. For example, zinc plays an important catalytic role  
 
in protein farnesyltransferase that catalyzes the addition of farnesyl isoprenoid to  
 
conserve cysteine in peptide or protein substrates (Huang et al., 1997). Zinc also occurs  
 
naturally in carbonic anhydrase, carboxypeptidase A, alcohol dehydrogenase and  
 
metallothionein (Parisi & Vallee, 1969). 
 
 
Physiologically, zinc is necessary for healthy immune system, normal growth and  
 
development, dark vision adaptation, fertility as well as renewal of skin cell. It has been  
 
shown that abnormalities of taste and sexual function in uremic patients could be  
 
improved significantly with the intake of zinc supplements (Mahajan et al., 1982).  
 
Besides, oral zinc supplementation also helped in the improvement of height velocity of  
 
short males (Kaji et al., 1998) and potentiated the effect of vitamin A in restoring night  
 
vision among night-blind pregnant women (Christian et al., 2001). Zinc possesses  
 
antioxidant properties which can retard oxidative processes (Powell, 2000). Zinc also  
 
affords beneficial effects to the barrier of the skin, gene regulation within lymphocytes,  
 
normal development and functioning of cells mediating the nonspecific immunity and  
 
acquired immunity (Shanker & Prasad, 1998). Consequently, zinc-deficient persons  
 
could experience increased susceptibility to a variety of pathogens.  
 
 
Diet is the main source of zinc. It can be found in meat based diet as well as milk, yogurt,  
 
beans, nuts, seeds and wholegrain cereals. The dose required by pregnant and lactating  
 
women would be higher than those under normal conditions (Tsalev & Zaprianov, 1983).  
 
 
 
 
  
1.3.2 PHYSICOCHEMICAL AND BIOLOGICAL PROPERTIES 
 
Zinc is the 23rd most abundant element in the earth crust. It is a transition metal in  
 
periodic table with atomic number 30. The atomic weight is 65.39 g/mol with valence of  
 
2. It has a high boiling and melting point of 907.0℃ and 419.5℃, respectively. Five  
 
stable isotopes have been discovered in nature.    
 
 
Zinc can be manufactured commercially into different types of salt form including zinc  
 
chloride, zinc sulphate, zinc gluconate and zinc lactate. The physicochemical properties  
 
of zinc vary for different salt forms. For example, zinc chloride and zinc gluconate are  
 
white, odourless powder while zinc sulphate is odourless but transparent powder (Parfitt,  
 
1999). In general, zinc salts can dissolve easily in water with the exception of  zinc  
 
carbonate and zinc oxide. 
 
 
Zinc is often referred as a “closed shell”, good Lewis acid which is unable to  
 
undergo redox reactions. At neutral pH, all acid-base catalysis in biological  
 
systems are catalysed by zinc (Kendrick et al., 1992).    
 
 
1.3.3 BIOAVAILABILITY AND PHARMACOKINETICS 
 
The gastrointestinal tract plays a vital role in zinc absorption, excretion and homeostatic  
 
control mechanism. In a perfusion study in human, Lee et al. (1989) revealed that zinc  
 
absorption occurred throughout the small intestine with the highest rate of absorption in  
 
jejunum. Zinc is also absorbed in the cecum and colon as shown in a rat study  
 
(Hara et al., 2000). Zinc is incompletely absorbed from the gastrointestinal tract. Its oral  
 
bioavailability is approximately 20 to 30% (Parfitt, 1999). 
 
 
 Zinc is absorbed through the transcellular and paracellular pathways (Steel & Cousins,  
 
1985). Hempe & Cousins (1991) suggested that cysteine-rich intestinal proteins that  
 
conferred metal-binding properties are important for zinc transport. After zinc passes  
 
through the barrier membrane of the intestinal mucosal cells, it will be taken up by  
 
albumin or globulin in the portal circulation to the liver (Fell & Lyon, 1994). A  
 
portion of zinc is extracted by hepatocytes. The remaining zinc will undergo tissue and  
 
cellular redistribution to maintain zinc homeostasis (King et al., 2000).    
 
 
An increase in zinc intake will increase the excretion of zinc in the stool but the urinary  
 
excretion remains unchanged (McCance & Widdowson, 1942). Other minor losses also  
 
occur in hair, nails, and epithelial skin cells (Tsalev & Zaprianov, 1983). 
 
 
1.4 MAGNESIUM 
 
1.4.1 INTRODUCTION 
 
Magnesium is the fourth most abundant cation the in human body, only exceeded by  
 
calcium, sodium and potassium (Herring et al., 1960). An adult body contains  
 
approximately 24 grams of magnesium, which are distributed in the muscles, tissues,  
 
extracellular fluids and bones (Gerstner, 2007). Magnesium is a cofactor in more than  
 
300 enzymatic reactions in human body. It is involved in various biological processes  
 
including enzymatic reactions catalyzed by creatine kinase, pyruvate kinase, leucine,  
 
aminopeptidase, RNA and DNA polymerase, deoxynucleotidyl transferase and  
 
phosphoglucomutase (Kendrick et al., 1992). Besides, it also plays a vital role in  
 
membrane function, energy metabolism and neuromuscular excitability. Toba et al.  
 
(2000) demonstrated that magnesium could promote bone formation, prevent  
 
bone resorption, and increase the dynamic strength of bone in ovariectomized rats.   
 
 
Deficiency of magnesium is common among the populations in developed countries  
 
such as the United States and France due to the changes in lifestyle and increased  
 
consumption of processed food (Ma et al., 1995, Rayssiguier et al., 2000 ). In addition,  
 
magnesium absorption can also be inhibited by certain dietary factors. Bohn et al. (2004)  
 
showed that fractional magnesium absorption could be impaired by phytic acid in a dose- 
 
dependent manner. Consequences of magnesium deficiency include cardiac arrhythmias,  
 
dysphagia, tremors, depression and eclampsia (Seelig, 1989).         
 
 
It is estimated that the daily requirement of magnesium is not more than 250 mg in  
 
normal adults, 150 mg in infants and 400 mg in pregnanct women (Herring et al., 1960).   
 
Food that is rich in magnesium includes legumes, whole grains, green leafy vegetables,  
 
nuts, coffee, chocolate and milk (Bernstein, 2002).      
 
 
1.4.2  PHYSICOCHEMICAL AND BIOLOGICAL PROPERTIES 
 
Magnesium is an alkali earth metal situated in Group II in periodic table with an atomic  
 
number of 12 and an atomic weight of 24.31 g/mol. It is the seventh most abundant  
 
element in the earth’s crust by mass and it exists in 3 stable isotopes: 24Mg, 25Mg, 26Mg.  
 
In nature, it is silvery white and very light. Thus, it has been used in the structural metal  
 
industry for a long time.  
 
  
Many types of magnesium salts such as magnesium lactate, magnesium oxide,  
 
magnesium pidolate and magnesium chloride have been used for the manufacturing of   
 
magnesium supplements. Similar with zinc, different magnesium salts have their  
 
own distinctive physicochemical properties. Magnesium gluconate is freely soluble in  
 
water but magnesium phosphate is practically insoluble in water (Parfitt, 1999). The rate  
 
at which magnesium is absorbed from the gastrointestinal tract also depends to a large  
 
extent on the form in which it is ingested (Tansy, 1971). 
 
 
In plants, magnesium plays a pivotal role in photosynthesis process. The structure  
 
of chlorophyll is consisted of a porphyrin ligand system and a central magnesium ion  
 
(Kendrick et al., 1992). The chemical structure of chlorophyll a is shown in Figure 1.4.  
 
Magnesium must be incorporated into the chlorophyll molecule before it can gather light  
 
for photosynthetic carbon reduction reactions (Sigel H. & Sigel A., 1990).   
 
 
 
 
                                         
 
                             
              Figure 1.4  Chemical structure of chlorophyll a (Kendrick et al., 1992) 
 
 
 
 
 
1.4.3  BIOAVAIABILITY AND PHARMACOKINETICS 
 
Approximately one third to one half of ingested magnesium is absorbed following  
 
oral administration and even soluble magnesium salts are generally very slowly  
 
absorbed (Parfitt, 1999). Magnesium absorption is dependent on the amount of  
 
endogenous magnesium ions present in rats (Tansy,1971). The principal site of  
 
magnesium absorption is the small intestine, with smaller amounts being absorbed in the  
 
colon (Konrad et al., 2003). It has been reported that magnesium is transported through  
 
the intestinal barrier via both transcellular and paracellular pathways (Schweigel &  
 
Martens, 2000, Sigel H. & Sigel A., 1990). Vitamin D may also play a major role in the  
 
transportation as magnesium absorption has been shown to be reduced in patients who  
 
had a deficiency of the active metabolite of vitamin D (Brannan et al., 1976).    
 
 
After magnesium passes through the barrier membrane of the gastrointestinal tract,  
 
about 35% of serum magnesium is bound to albumin and globulin while the rest remain  
 
ionized (Herring et al., 1960). It is then distributed to bone, muscle, soft tissue and  
 
extracellular fluid. Approximately 30% of the magnesium present in the bone is  
 
exchangeable and functions as a reservoir to stabilize the serum concentration  
 
(Swaminathan, 2003).  
 
 
Magnesium homeostasis is not regulated by hormone. Instead, it depends on the  
 
balance between intestinal absorption and renal excretion. Under normal circumstances  
 
in human, the renal excretion is about 120-140 mg/ 24hr (Sigel H. & Sigel A., 1990) and  
 
95% of the excreted magnesium is reabsorbed from the proximal tubular segments, thick  
 
ascending limb of Henle’s loop and distal segments. During magnesium deficiency,  
 
the kidney will reduce magnesium loss in urine. This was further confirmed by Dengel  
 
et al. (1994) that lactating women would compensate magnesium losses in breast milk  
 
by reducing urinary magnesium losses.    
 
1.5 SUMMARY AND SCOPE OF STUDY 
 
As mentioned earlier, inulin is a plant carbohydrate which can benefit human health in  
 
many ways. One of the benefits is the enhancement of mineral absorption from the  
 
gastrointestinal tract. In recent studies, inulin is shown to be able to promote mineral  
 
absorption through paracellular pathway in vitro. However, this has yet to be borne out  
 
in in vivo studies.    
 
 
Thus, the present study was conducted to investigate the potential of co-administered  
 
inulin in enhancing zinc and magnesium absorption. Besides, acyclovir and atenolol,   
 
which are amenable to be transported paracellularly, were also used as model drugs to  
 
investigate the enhancement effect of inulin. The study was conducted in various stages  
 
with the following objectives:   
 
1. To develop a simple flame atomic absorption spectrophotometry method  
 
for the determination of zinc and magnesium in rat plasma; 
 
2. To determine the absolute bioavailability of zinc gluconate and magnesium  
 
lactate in male Sprague-Dawley rats; 
 
3. To study the effect of different doses of inulin on the oral bioavailability of 
 
zinc gluconate and magnesium lactate using a rat model; 
 
4.          To assess the effect of different dose of inulin on the oral bioavailability  
 
of 2 model drugs, acyclovir and atenolol using a rat model.  
 
 
CHAPTER 2 
 
DEVELOPMENT OF ATOMIC ABSORPTION SPECTROPHOTOMETRY 
 
METHODS FOR THE ANALYSIS OF ZINC AND MAGNESIUM IN HUMAN 
 
PLASMA 
 
 
 
2.1   INTRODUCTION 
 
Different techniques for the analysis of zinc and magnesium concentration in plasma  
 
have been reported in the literature. They included ion chromatography (Lane et al.,  
 
1999), capillary zone electrophoresis (Nemutlu and Özaltın, 2005), flame photometric  
 
method (Willis, 1959, Alcock et al., 1960), colorimetric method (Garner, 1946), flame  
 
emission (Pruden et al., 1966) and flame atomic absorption spectrophotometer (Pruden et  
 
al., 1966)  
 
 
In earlier times, colorimetric method was commonly used for determination of trace  
 
elements. The sample preparation procedures involved protein precipitation by  
 
trichloroacetic acid, addition of either Titan yellow or Magon sulfate reagents to the  
 
resulting water-clear filtrate followed by element precipitation (Garner, 1946). The  
 
associated problems with this method were low stability of the elements and high blank  
 
absorbance of the reagents (Loannou & Konstantianos, 1989). Using another method in  
 
analyzing elements, Lane et al. (1999) showed that ion chromatography had the  
 
advantage of determining multiple elements in one sample of 25 µl volume and offered a  
 
more cost effective choice. However, the sample required laborious microwave digestion  
 
in the sample pre-treatment. Fluorometric method has been used to determine plasma  
 
magnesium concentration. In spite of the high sensitivity of the fluorometric method, it  
has a few disadvantages such as low reagent stability and low stability of magnesium  
 
complexes.  These were overcome by using 2-hydroxy-1-naphthaldehyde  
 
salicyloylhydrazone (HNASH) as the fluorometric reagent which is stable in alkaline  
 
media. Sodium chloride was also added to stabilize HNASH-magnesium complexes  
 
(Loannou & Konstantianos,1989).   
 
 
An alternative technique for the quantification of zinc and magnesium in plasma is  
 
atomic absorption spectrophotometer (AAS). Flameless AAS with graphite furnace  
 
atomizers has high sensitivity and requires only a small volume of sample for analysis  
 
(Vieira & Hansen, 1981, Haese et al., 1992). However, it requires an expensive special  
 
attachment for the AAS (Makino & Takahara, 1981). On the other hand, flame AAS  
 
technique is more commonly employed in laboratories due to its simplicity, specificity  
 
and lower cost. However, bulk-matrix effects can cause different uptake rate and affect  
 
the accuracy of analysis (Smith & Butrimovitz, 1979). Other drawbacks of flame AAS  
 
include clogging of the burner head or nebulizer by the proteins and salts in the plasma  
 
and the presence of chemical interferences (Haese et al., 1992). Thus, certain sample pre- 
 
treatments are needed. Some workers suggested the addition of a solution containing  
 
0.444 mM potassium dihydrogen phosphate and 3.33% (v/v) perchloric acid or  
 
trichloroacetic acid for the deproteinization of the plasma (Pruden et al., 1966, Gimblet et  
 
al., 1967). Standard addition calibration and preconcentration techniques were also used  
 
to eliminate the bulk-matrix effects of the plasma samples with the aqueous working  
 
standards (Tsalev, 1984).  Simple dilution, consisting of 1 part plasma to 1 part water or  
 
1 part plasma with 4 part water, was also often practiced so that the dilution did not  
 
cause low sensitivity to the method (Tsalev, 1984). However, direct dilution consisting of  
